Cargando…

S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS

Detalles Bibliográficos
Autores principales:	Telen, M, Saraf, S, Cruz, K, Idowu, M, Kalfa, T, Osunkwo, I, Hagar, R, Geib, J, Forsyth, S, Schroeder, P, Wu, E, Kelly, P, Brown, R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Oral Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811875/ http://dx.doi.org/10.1097/01.HS9.0000821404.03661.11

Ejemplares similares

O-03: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH
por: M., TELEN, et al.
Publicado: (2022)

Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT‐4202), an Allosteric Activator of Pyruvate Kinase‐R, in Healthy Adults: A Randomized, Placebo‐Controlled, Double‐Blind, First‐in‐Human Phase 1 Trial
por: Forsyth, Sanjeev, et al.
Publicado: (2022)

P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH
por: Saraf, S., et al.
Publicado: (2022)

S103: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE PKR ACTIVATOR ETAVOPIVAT (FT-4202) IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE
por: Lal, A., et al.
Publicado: (2022)

P-055: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE
por: T., COATES, et al.
Publicado: (2022)

PB2232: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE
por: Lal, A., et al.
Publicado: (2022)

Intravascular Hemolysis in Aluminum Phosphide Poisoning
por: Malakar, Sayan, et al.
Publicado: (2019)

Naphthalene Toxicity: Methemoglobinemia and Acute Intravascular Hemolysis
por: Volney, Giselle, et al.
Publicado: (2018)

Clostridium perfringens Septicemia with Massive Intravascular Hemolysis
por: Fujikawa, Hirohisa, et al.
Publicado: (2019)

Massive intravascular hemolysis associated with Clostridium perfringens bacteremia
por: Poletti, Giovanni, et al.
Publicado: (2021)

A case of severe intravascular hemolysis in a young girl
por: Shastry, Shamee, et al.
Publicado: (2011)

Characterization of Renal Injury and Inflammation in an Experimental Model of Intravascular Hemolysis
por: Merle, Nicolas S., et al.
Publicado: (2018)

Babesia microti Causing Intravascular Hemolysis in Immunocompetent Child, China
por: Yao, Jiafeng, et al.
Publicado: (2023)

Fetal hemoglobin and hemolysis markers in sickle cell anemia()
por: Colella, Marina Pereira, et al.
Publicado: (2015)

Selenium Status and Hemolysis in Sickle Cell Disease Patients
por: Delesderrier, Emília, et al.
Publicado: (2019)

Massive acute intravascular hemolysis after platelet transfusion: An unrecognized entity
por: Jain, Vishakha V., et al.
Publicado: (2011)

Acute intravascular hemolysis due to naphthalene toxicity: a case report
por: Uthuman, A. A. A., et al.
Publicado: (2019)

Intravascular hemolysis and multitreatment predict thrombosis in patients with autoimmune hemolytic anemia
por: Fattizzo, Bruno, et al.
Publicado: (2022)

Role of Toll‐like receptor 4 in intravascular hemolysis‐mediated injury
por: Vázquez‐Carballo, Cristina, et al.
Publicado: (2022)

Intravascular Hemolysis, Methemogolbinemia and Acute Renal Failure in a Young Female
por: Gupta, Ashish, et al.
Publicado: (2023)

Intravascular Hemolysis and Septicemia due to Clostridium perfringens Emphysematous Cholecystitis and Hepatic Abscesses
por: Cochrane, Justin, et al.
Publicado: (2015)

Intravascular Hemolysis following Acute Zinc Phosphide Poisoning; a Case Report
por: Ramezani, Zana, et al.
Publicado: (2018)

Sudden death caused by Clostridium perfringens sepsis presenting as massive intravascular hemolysis
por: Chinen, Katsuya
Publicado: (2020)

Pyridoxamine: another vitamin for sickle cell disease?
por: Telen, Marilyn J.
Publicado: (2020)

Higher Rates of Hemolysis Are Not Associated with Albuminuria in Jamaicans with Sickle Cell Disease
por: Asnani, Monika R., et al.
Publicado: (2011)

PB2524: TRIAL IN PROGRESS: THE HIBISCUS-KIDS STUDY, A SINGLE-ARM, OPEN-LABEL, PHASE 1/2 STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF ETAVOPIVAT IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE
por: Colombatti, Raffaella, et al.
Publicado: (2023)

Rifampin-Induced Acute Intravascular Hemolysis Leading to Heme Pigment-Related Kidney Injury
por: Sanwal, Chandra, et al.
Publicado: (2020)

Pathogenic Characterization of Clostridium perfringens Strains Isolated From Patients With Massive Intravascular Hemolysis
por: Suzaki, Ai, et al.
Publicado: (2021)

Acute Cytomegalovirus Illness in an Immunocompetent Adult Causing Intravascular Hemolysis and Suspected Hemophagocytic Lymphohistiocytosis
por: Elliott, Ross P., et al.
Publicado: (2022)

Low grade intravascular hemolysis associates with peripheral nerve injury in type 2 diabetes
por: Le Jeune, Sylvain, et al.
Publicado: (2022)

Biomarkers and recent advances in the management and therapy of sickle cell disease
por: Telen, Marilyn J.
Publicado: (2015)

Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease
por: Osunkwo, Ifeyinwa, et al.
Publicado: (2020)

Experimental intravascular hemolysis induces hemodynamic and pathological pulmonary hypertension: association with accelerated purine metabolism
por: Bilan, Victor P., et al.
Publicado: (2018)

Effects of Hypoxia on Erythrocyte Membrane Properties—Implications for Intravascular Hemolysis and Purinergic Control of Blood Flow
por: Grygorczyk, Ryszard, et al.
Publicado: (2017)

Renal hemosiderosis secondary to intravascular hemolysis after mitral valve repair: A case report
por: Lee, In Hee, et al.
Publicado: (2020)

Beyond the Definitions of the Phenotypic Complications of Sickle Cell Disease: An Update on Management
por: Ballas, Samir K., et al.
Publicado: (2012)

Low bone mass density is associated with hemolysis in brazilian patients with sickle cell disease
por: Baldanzi, Gabriel, et al.
Publicado: (2011)

Doppler velocimetry of the orbital arteries in patients with sickle cell anemia: relationship with biomarkers of hemolysis
por: Ferrão, Thiago de Oliveira, et al.
Publicado: (2017)

Lactate dehydrogenase and hemolysis index to predict vaso-occlusive crisis in sickle cell disease
por: Feugray, Guillaume, et al.
Publicado: (2023)

Intravascular hemolysis associated with Candidatus Mycoplasma hematoparvum in a non-splenectomized dog in the south region of Iran
por: Sharifiyazdi, Hassan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1ot9e2vdom2r9mokk3a5t8c5lu